Clinical trial · Interventional
Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
A Feasibility Study of Orchiectomy in Patients With Prostate Cancer on Chronic LHRH Agonist or Antagonist Therapy
NCT04705038CI-TRIAL-00106490completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to learn how an educational intervention about orchiectomy as an alternative to medical castration for those who are already on medical castration will impact the number of patients willing to undergo an orchiectomy (surgery to remove the testicles).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patient Education | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Educational Intervention
- description
- Participants in this arm undergo a short educational session about orchiectomy. They will also be asked to complete questionnaires.
- interventionNames
- Behavioral: Patient Education
- type
- NO_INTERVENTION
- label
- No Intervention
- description
- Participants that decline the education session will continue with routine care of their cancer. They will also be asked to complete questionnaires.
Primary outcomes (1)
- measure
- Number of patients that undergo orchiectomy after receiving study education intervention
- timeFrame
- 1 year
Secondary outcomes (6)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of metastatic prostatic adenocarcinoma * Receiving luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist therapy continuously for at least 1 year with anticipated lifelong therapy * Able to complete written surveys in English Exclusion Criteria: * More than 2 prior systemic treatment regimens utilized in addition to castration.
References
Publications (0)
Data not yet available
No reference posted for this study.